More on tumeric, excerpted from the article I posted in Articles of Interest, titled "Cancer/Chemotherapy/Supplements;
http://www.lef.org/protocols/prtcls-...prtcl-024.html
"...Curcumin, an extract of the spice turmeric, is synergistic with genistein and inhibits angiogenic growth signals emitted by tumor cells. Curcumin acts via a different mechanism than genistein to inhibit the EGF receptor but is up to 90% effective in a dose-dependent manner. It is important to note that while curcumin has been shown to be up to 90% effective in inhibiting the expression of the EGF receptor on cancer cell membranes, this does not mean that it will be effective in 90% of cancer patients or reduce tumor volume by 90%. Because two-thirds of all cancers, however, over-express the EGR receptor and such overexpression frequently fuels the metastatic spread of cancer throughout the body, the suppression of this receptor is desirable.
Curcumin has a number of other antiangiogenic properties that appear to be synergistic with metronomic dosing chemotherapy. These potential synergistic and/or additive mechanisms include:
Inhibition of the induction of basic fibroblast growth factor (bFGF). bFGF is both a potent mitogen (growth signal) for many cancers and an important signaling factor in angiogenesis (Arbiser et al. 1998).
Inhibition of the induction of hepatocyte growth factor (HGF), overexpression is involved in hepatocellular (liver cell-related) carcinoma (Seol et al. 2000).
Inhibition of the expression of COX-2, the enzyme involved in the production of PGE-2, a tumor-promoting prostaglandin (Zhang et al. 1999).
Inhibition of a transcription factor in cancer cells known as nuclear factor-kappa B (NF-KB). Many cancers overexpress NF-KB and use this as a growth vehicle to escape regulatory control (Plummer et al. 1999).
Increased expression of nuclear p53 protein in human basal cell carcinomas, hepatomas, and leukemia cell lines, which increases apoptosis (Jee et al. 1998)...."
Linear Mode
